| International Session (Symposium) 2 (JSH・JSGE) |
| Thu. November 1st 14:40 - 17:00 Room 13: Kobe International Conference Center International Conference Room |
| Investigation of viral factor associated with HCC occurrence after antiviral therapy through HCV full-open reading frame analysis | |||
| Shinya Maekawa1, Minoru Sakamoto1, Nobuyuki Enomoto1 | |||
| 1The First Department of Internal Medicine, University of Yamanashi | |||
|
|||
|
|||
| (Background) Due to the recent advances in antiviral therapy, sustained viral response (SVR) became possible in most of CH-C patients. However, since the occurrence of hepatocellular carcinoma is observed at a certain frequency, it is an urgent to elucidate HCC risks in those patients. (Methods) (1)In 129 genotype-1b HCV patients receiving peginterferon (PEG-IFN) plus ribavirin (RBV) therapy, viral region associated with post-treatment HCC occurrence was examined by direct sequencing of an HCV whole open reading frame (ORF) obtained prior to the therapy. (2)In 277 interferon-free SVR HCV-1b patients, the association between HCC occurrence (5/277, 1.8%)/ recurrence (9%) after SVR and the pretreatment HCV core 70/ NS5A-Y93 sequences were investigated. (Results) (1)SVR was achieved in 51% (66/129), and 14 patients developed HCC (14/129, 11%) after the therapy overall while three patients developed HCC after achieving SVR (3/66, 4.5%). In the HCV-ORF analysis, the strongest association was noted in core 70 amino acids (p = 4.0 E-5). In subclass analysis, core 70 amino acid was associated with HCC occurrence in SVR patients (p=0.007) as well as non-SVR patients (p=0.04). (2)Core 70Q was observed in patients with HCC occurrence (2/4), HCC recurrence (13/22) and no-HCC (94/229) (HCC occurrence/recurrence vs. no HCC, p=0.12). Likewise, NS5A-Y93H was observed in patients with HCC occurrence (0/5), HCC recurrence (0/25) and no-HCC (38/242) (HCC occurrence/recurrence vs. no HCC, p=0.016). (Conclusions) In PEG-IRN/RBV therapy, core 70 amino acid is involved in HCC development even after virus disappearance. In IFN-free DAA therapy, in addition to core 70, NS5A-Y93H was also suggested to affect the future HCC development. |
|||
|
Index Term 1: HCV Index Term 2: Post-treatment HCC |
|||
| Page Top | |||